RBC Capital raised the firm’s price target on Ligand (LGND) to $141 from $140 and keeps an Outperform rating on the shares ahead of its Investor Day next week. The management is expected to introduce 2025 guidance, usually viewed as conservative, and also update its long-term outlook, the analyst tells investors in a research note. RBC adds that it also expects to receive further insights into the ramp-up of the products launched this year, namely Capvaxive and Ohtuvayre.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on LGND:
- Ligand price target raised to $147 from $135 at Oppenheimer
- Ligand price target raised to $150 from $125 at Barclays
- Ligand Pharmaceuticals Reports Strong Q3 2024 Growth
- Ligand reports Q3 EPS $1.84, consensus $1.35
- Ligand raises FY24 EPS view to $5.50-$5.70, consensus $5.39
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
